Phase I/II Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection

Trial Profile

Phase I/II Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs INO 8000 (Primary) ; INO 9012
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2016 According to Inovio Pharmaceuticals media release, in April 2016, the company partnered with National Cancer Institute and Mayo Clinic to initiate this trial.
    • 16 Apr 2015 Status changed from planning to not yet recruiting, according to ClinicalTrials.gov record.
    • 13 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top